53 related articles for article (PubMed ID: 11464901)
1. Detailed molecular analysis of 1p36 in neuroblastoma.
White PS; Thompson PM; Seifried BA; Sulman EP; Jensen SJ; Guo C; Maris JM; Hogarty MD; Allen C; Biegel JA; Matise TC; Gregory SG; Reynolds CP; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):37-41. PubMed ID: 11464901
[TBL] [Abstract][Full Text] [Related]
2. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.
Vandepoele K; Andries V; Van Roy N; Staes K; Vandesompele J; Laureys G; De Smet E; Berx G; Speleman F; van Roy F
PLoS One; 2008 May; 3(5):e2207. PubMed ID: 18493581
[TBL] [Abstract][Full Text] [Related]
3. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome.
Heilstedt HA; Ballif BC; Howard LA; Lewis RA; Stal S; Kashork CD; Bacino CA; Shapira SK; Shaffer LG
Am J Hum Genet; 2003 May; 72(5):1200-12. PubMed ID: 12687501
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma: biological insights into a clinical enigma.
Brodeur GM
Nat Rev Cancer; 2003 Mar; 3(3):203-16. PubMed ID: 12612655
[TBL] [Abstract][Full Text] [Related]
6. Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma.
Ung CY; Levee TM; Zhang C; Correia C; Yeo KS; Li H; Zhu S
Comput Struct Biotechnol J; 2022; 20():3291-3303. PubMed ID: 35832612
[TBL] [Abstract][Full Text] [Related]
7. Targeting lipid metabolism in cancer: neuroblastoma.
Agostini M; Melino G; Habeb B; Calandria JM; Bazan NG
Cancer Metastasis Rev; 2022 Jun; 41(2):255-260. PubMed ID: 35687185
[No Abstract] [Full Text] [Related]
8. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
[TBL] [Abstract][Full Text] [Related]
9. From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.
Decaesteker B; Durinck K; Van Roy N; De Wilde B; Van Neste C; Van Haver S; Roberts S; De Preter K; Vermeirssen V; Speleman F
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945759
[TBL] [Abstract][Full Text] [Related]
10. CHD5 inhibits metastasis of neuroblastoma.
Laut AK; Dorneburg C; Fürstberger A; Barth TFE; Kestler HA; Debatin KM; Beltinger C
Oncogene; 2022 Jan; 41(5):622-633. PubMed ID: 34789839
[TBL] [Abstract][Full Text] [Related]
11. Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma.
Afanasyeva EA; Gartlgruber M; Ryl T; Decaesteker B; Denecker G; Mönke G; Toprak UH; Florez A; Torkov A; Dreidax D; Herrmann C; Okonechnikov K; Ek S; Sharma AK; Sagulenko V; Speleman F; Henrich KO; Westermann F
Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33658318
[TBL] [Abstract][Full Text] [Related]
12. Developing preclinical models of neuroblastoma: driving therapeutic testing.
Ornell KJ; Coburn JM
BMC Biomed Eng; 2019; 1():33. PubMed ID: 32903387
[TBL] [Abstract][Full Text] [Related]
13. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.
García-López J; Wallace K; Otero JH; Olsen R; Wang YD; Finkelstein D; Gudenas BL; Rehg JE; Northcott P; Davidoff AM; Freeman KW
Cell Rep; 2020 Jan; 30(2):454-464.e5. PubMed ID: 31940489
[TBL] [Abstract][Full Text] [Related]
14. Systematic computational identification of prognostic cytogenetic markers in neuroblastoma.
Qin C; He X; Zhao Y; Tong CY; Zhu KY; Sun Y; Cheng C
BMC Med Genomics; 2019 Dec; 12(1):192. PubMed ID: 31831008
[TBL] [Abstract][Full Text] [Related]
15. Research progress of neuroblastoma related gene variations.
Cao Y; Jin Y; Yu J; Wang J; Yan J; Zhao Q
Oncotarget; 2017 Mar; 8(11):18444-18455. PubMed ID: 28055978
[TBL] [Abstract][Full Text] [Related]
16. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Bosse KR; Maris JM
Cancer; 2016 Jan; 122(1):20-33. PubMed ID: 26539795
[TBL] [Abstract][Full Text] [Related]
17. PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.
Benedetti E; Galzio R; D'Angelo B; Cerù MP; Cimini A
PPAR Res; 2010; 2010():427401. PubMed ID: 20339586
[TBL] [Abstract][Full Text] [Related]
18. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
19. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death.
Munirajan AK; Ando K; Mukai A; Takahashi M; Suenaga Y; Ohira M; Koda T; Hirota T; Ozaki T; Nakagawara A
J Biol Chem; 2008 Sep; 283(36):24426-34. PubMed ID: 18614535
[TBL] [Abstract][Full Text] [Related]
20. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
